J&J Not Seeking To Undercut Incivek, Victrelis On Olysio’s Pricing
Executive Summary
While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.
You may also be interested in...
Medicare Will Be Leading Payer For Hepatitis C By 2017 – Milliman Report
Commissioned by Janssen Therapeutics, the report focuses on how a number of changes in the U.S. health care environment will increase access to diagnosis and treatment for patients with hepatitis C and also change who pays for care.
FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos
Pricing means an $84,000 cost of therapy for some HCV patients, but $168,000 for others. The nucleotide polymerase inhibitor will be dosed with ribavirin but eliminates interferon for patients with genotypes 2 and 3, making it the first all-oral therapeutic regimen.
FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos
Pricing means an $84,000 cost of therapy for some HCV patients, but $168,000 for others. The nucleotide polymerase inhibitor will be dosed with ribavirin but eliminates interferon for patients with genotypes 2 and 3, making it the first all-oral therapeutic regimen.